{"disease":{"id":"attr-cm","name":"attr cm"},"drugs":{"marketed":[{"drug_id":"acoramidis","indication_name":"Cardiomyopathy of ATTR-CM","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Attruby","generic_name":"ACORAMIDIS","company_name":"Bridgebio Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Attruby works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."},{"drug_id":"acoramidis","indication_name":"cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Attruby","generic_name":"ACORAMIDIS","company_name":"Bridgebio Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Attruby works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."}],"pipeline":[{"drug_id":"vyndamax-tafamidis-61mg","indication_name":"ATTR-CM (Transthyretin Amyloid Cardiomyopathy)","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndamax (tafamidis 61mg)","generic_name":"vyndamax-tafamidis-61mg","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"As prescribed in real world practice","quality_score":0,"revenue":null,"mechanism":"As prescribed in real world practice"}],"offLabel":[],"totalMarketed":2,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT07338942","title":"Implementation of Standardized Early Identification and Diagnosis for Transthyretin Amyloidosis (ATTR) in High-Risk Populations","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":4000,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07235462","title":"A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06465810","title":"Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis","phase":"","overall_status":"RECRUITING","enrollment_count":1850,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07207811","title":"CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1280,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT03842163","title":"Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology","phase":"","overall_status":"COMPLETED","enrollment_count":812,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06836011","title":"A Multicenter Study on Atrioventricular Regurgitation in Transthyretin Amyloid Cardiomyopathy: Definition, Prevalence, and Prognostic Impact.","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Medical University of Vienna","has_results":false},{"nct_id":"NCT06029452","title":"A Retrospective Validation Study To Identify Chart-Based Clinical Diagnosis Of Wild-Type Transthyretin Amyloid Cardiomyopathy (Attrwt-CM) And Non-Amyloid Heart Failure Among Patients With Heart Failure (HF).","phase":"","overall_status":"COMPLETED","enrollment_count":558,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05776212","title":"Quantitative-imaging in Cardiac Transthyretin Amyloidosis","phase":"","overall_status":"RECRUITING","enrollment_count":140,"lead_sponsor_name":"University of Edinburgh","has_results":false},{"nct_id":"NCT04801329","title":"Korean Post-marketing Surveillance Vyndamax® Capsules for the Treatment of Transthyretin Amyloid Cardiomyopathy","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":110,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT06338696","title":"Thailand ATTR-CM Registry","phase":"","overall_status":"RECRUITING","enrollment_count":105,"lead_sponsor_name":"Mahidol University","has_results":false},{"nct_id":"NCT05442047","title":"A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT06260709","title":"A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT06393465","title":"Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy","phase":"","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT03458130","title":"Study of AG10 in Amyloid Cardiomyopathy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Eidos Therapeutics, a BridgeBio company","has_results":true},{"nct_id":"NCT00935012","title":"Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05139680","title":"A Study to Examine the Clinical Effectiveness of Tafamidis in Patients With Mixed Phenotype Hereditary Transthyretin Amyloidosis","phase":"","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05210010","title":"A Prospective Study to Assess the Utility of CA-4F in a Canadian Cardiology Setting","phase":"NA","overall_status":"UNKNOWN","enrollment_count":8,"lead_sponsor_name":"Ensho Health Intelligent Systems Inc.","has_results":false},{"nct_id":"NCT07494656","title":"A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyopathy in Germany","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1,"lead_sponsor_name":"Pfizer","has_results":false}],"total":18},"guidelines":[],"source":"Drug Landscape verified database"}